Factor VIII gene therapy (Corautus Genetics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFactor VIII gene therapy (Corautus Genetics)
Drug Alias Name第八因子基因疗法Factor VIII MAXIMUM-AD八因子基因疗法MAX-AD Factor VIII gene therapy
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor VIII modulatorsFactor VIII gene transference
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBaxter International IncVia Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaxter International IncVia Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A